Riding the J&J Dealmaking Wave: Biotechs Ink New Pact for Potential First-in-Class IBD Therapy
Fresh off the successful $1.25 billion acquisition of Yellow Jersey Therapeutics by Johnson & Johnson, Kaken Pharmaceutical and Numab Therapeutics ...
Tag: Numab Therapeutics
Post-J&J Buyout, Biotech Duo Strikes New Immunology Deal: Targeting Next-Gen IBD Therapy
Riding the wave of success from Johnson & Johnson's acquisition of Yellow Jersey Therapeutics, Kaken Pharmaceutical and Numab Therapeutics are ...
Popular Stories
-
Cybin Inc: The Psychedelic Revolution in Mental Health Treatment is Here
-
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
-
BlackRock Bitcoin ETF Sees Rally: What’s Next for IBIT?
-
Universal Digital Inc. (Formerly Minas Metals Ltd.) Announces Completion of Change of Business
-
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Small Cap Bulls is your trusted source for uncovering small-cap companies on the brink of explosive growth. With in-depth analysis and expert insights, we help investors navigate the dynamic world of small-cap stocks. Join us as we charge ahead, empowering your investment journey.
2024 Small Cap Bulls – Charging Ahead. All Rights Reserved.
By using this site you agree to the Terms of Use, Privacy Policy, and Service Agreement.
Navigate
stay connected
Join our newsletter